Table 1.
RA and healthy control cohort characteristics.
| RA subjects (n = 110) | Control subjects (n = 93) | |
|---|---|---|
| Age at draw (mean ± SD years) | 51.7 ± 14.9 | 46.3 ± 14.2 |
| Male/Female | 24/86 | 25/68 |
| Race | 94.6% Caucasian,5.4% other | 91.4% Caucasian, 8.6% other |
| Disease duration (mean ± SD years) | 6.8 ± 8.4 | |
| RAPID3 score (mean ± SD) | 3.1 ± 2.2 | |
| CCP+ | 60.9% | |
| RF+ | 57.3% | |
| Therapy | 15% Steroid 50.9% DMARD 40% NSAID 10% Biologic |
RAPID3, the routine assessment of patient index data with 3 measures (0–9); CCP, cyclic citrullinated peptide; RF, rheumatoid factor. Steroid therapy includes: prednisone (5–20 mg/day); DMARD includes: methotrexate (10–25 mg/week or 10 mg/2X weekly), sulfasalazine, hydroxychloroquine (200 mg/2X or 1X daily), azathioprine, and leflunomide; NSAID includes: ibuprofen, naproxen, aspirin, meloxicam, and celecoxib; and biologics includes: etanercept, abatacept, infliximab, and adalimumab.